We report 28 @entity1 with advanced @entity2132 ( @entity2132 ) treated with extracorporeal photopheresis (ECP). All had failed conventional immunosuppressive therapy. Of the @entity1 , 27 had extensive @entity2132 and 20 had more than 50% cutaneous surface area involvement. ECP was initiated approximately 2 years after onset of @entity2132 and 3 years following allogeneic stem cell transplantation and administered fortnightly for 4 months and then monthly. Response was assessed using quantifiable disease measures, including skin score, liver function tests (LFTs), blood counts, and lung function tests. Regression analysis allowed assessment of any pretreatment clinical or laboratory parameters that predicted response. There were 25 @entity1 who completed 3 months and 21 who completed 6 months of treatment. Systemic immunosuppression was stable or reduced in 86% of @entity1 . There were 3 @entity1 who died from @entity2132 . After 6 months, median skin scores were 53% lower (P =.003) in sclerodermoid and lichenoid disease. Of 6 @entity1 with mucosal ulceration, 3 improved. A nonsignificant improvement of LFTs occurred. We infer that ECP is effective even in @entity1 with extensive cutaneous @entity2132 of 2 years duration that is resistant to conventional therapy. Furthermore, both sclerodermoid and lichenoid subtypes responded. However, no baseline parameters predicted a favorable response to ECP, so @entity1 selection must continue to be made on clinical grounds.

Influence of extracorporeal photopheresis on clinical and laboratory parameters in XXXX and analysis of predictors of response.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity2132 :: ('MESH:D006086', 'Disease') :: ['chronic graft-versus-host disease', 'cGVHD']
@entity2132 :: (MESH:D006086,Disease) :: ['chronic graft-versus-host disease']
